| Patents for A61P 43 - Drugs for specific purposes, not provided for in groups (156,317) |
|---|
| 09/16/1999 | WO1999033979A3 Bone marrow secreted proteins and polynucleotides |
| 09/16/1999 | WO1999033858A3 Estrone sulfamate inhibitors of estrone sulfatase, and associated pharmaceutical compositions and methods of use |
| 09/16/1999 | WO1999032082A3 Pharmaceutical compositions |
| 09/16/1999 | WO1999029878A3 Methods of producing anti-angiogenic proteins: endostatin, angiostatin or restin, using a pichia yeast expression system |
| 09/16/1999 | WO1999029321A9 Inhibition of membrane-associated viral replication |
| 09/16/1999 | WO1999028304A9 Pdgf receptor kinase inhibitory compounds, their preparation and compositions |
| 09/16/1999 | WO1999025831A3 Slit polypeptide and method of modulation of robo with ligands |
| 09/16/1999 | WO1998056759A3 Novel pentaerythrite derivatives, the production and use thereof and intermediate products for the synthesis of the same |
| 09/16/1999 | CA2683097A1 Novel opiate compounds, methods of making and methods of use |
| 09/16/1999 | CA2659664A1 Improved radiation therapy methods |
| 09/16/1999 | CA2332114A1 Novel delivery of hydroxy carboxylic acids |
| 09/16/1999 | CA2323496A1 Enzyme inhibitors |
| 09/16/1999 | CA2323490A1 inhibition of angiogenesis |
| 09/16/1999 | CA2323460A1 Plasminogen-related gene b polypeptides |
| 09/16/1999 | CA2323448A1 Methods of inhibiting bone resorption |
| 09/16/1999 | CA2323236A1 Human receptor proteins; related reagents and methods |
| 09/16/1999 | CA2323210A1 Enhancement of intracellular delivery and tissue targeting of drugs and genes |
| 09/16/1999 | CA2323208A1 Vitronectin receptor antagonists |
| 09/16/1999 | CA2323177A1 Composition |
| 09/16/1999 | CA2323089A1 Inhibitors of type 5 and type 3 17.beta.-hydroxysteroid dehydrogenase and methods for their use |
| 09/16/1999 | CA2322962A1 Phenanthrofuran derivatives |
| 09/16/1999 | CA2322873A1 Halogenated amidino amino acid derivatives useful as nitric oxide synthase inhibitors |
| 09/16/1999 | CA2322848A1 Novel methods for treating disorders in which docosahexaenoic acid (dha) levels are effected |
| 09/16/1999 | CA2322839A1 Peptide compositions and formulations and use of same |
| 09/16/1999 | CA2322824A1 Combination therapy and composition for acute coronary ischemic syndrome and related conditions |
| 09/16/1999 | CA2322743A1 Fibrinogen receptor antagonists |
| 09/16/1999 | CA2322618A1 Methods of diagnosis and triage using cell activation measures |
| 09/16/1999 | CA2322508A1 Modified factor viii |
| 09/16/1999 | CA2321935A1 Use of alpha-rar antagonists for inhibition of mucin secretion |
| 09/16/1999 | CA2321834A1 Amino anthracyclinone derivatives and their use in the treatment of amyloidosis |
| 09/16/1999 | CA2320718A1 Lipoic acid analogs |
| 09/15/1999 | EP0941994A1 Pyrazolopyrimidines and pyrazolotriazines with 5-HT6 receptor affinity |
| 09/15/1999 | EP0941992A1 Ipriflavone preparation process |
| 09/15/1999 | EP0941356A2 Stabilized transient gene expression |
| 09/15/1999 | EP0941342A1 Human squalene epoxidase |
| 09/15/1999 | EP0941330A1 Therapeutic compositions and methods for treating disease states with myeloid progenitor inhibitory factor-1 (mpif-1), monocyte colony inhibitory factor (m-cif), and macrophage inhibitory factor-4 (mip-4) |
| 09/15/1999 | EP0941323A1 Bone morphogenetic protein-16 (bmp-16) compositions |
| 09/15/1999 | EP0941322A2 Bovine lactation associated immunotropic protein (cd14), encoding gene and application in b cell activation |
| 09/15/1999 | EP0941319A1 Peptides capable of inhibiting the endocytosis of the app and corresponding nucleotide sequences |
| 09/15/1999 | EP0941316A1 Human p2x purinoreceptor |
| 09/15/1999 | EP0941253A1 New butyric esters with antiproliferative activity and the pharmaceutical compositions containing them |
| 09/15/1999 | EP0941247A2 Peptide compounds useful for modulating fgf receptor activity |
| 09/15/1999 | EP0941245A1 Promoter for smooth muscle cell expression |
| 09/15/1999 | EP0941243A1 Polypeptides comprising gax protein domains, involved in repressing transcription and/or interacting with other proteins, corresponding nucleic acids and their use |
| 09/15/1999 | EP0941242A2 Secreted proteins and polynucleotides encoding them |
| 09/15/1999 | EP0941239A1 Vertebrate homologues of unc-53 protein of c. elegans |
| 09/15/1999 | EP0941238A2 Mutant forms of fas ligand and uses thereof |
| 09/15/1999 | EP0941224A1 Multivalent salts of pyridostigmine and related compounds |
| 09/15/1999 | EP0941120A1 Branched peptide linkers |
| 09/15/1999 | EP0941112A1 Methods and compositions for stimulating neurite growth using compounds with affinity for fkbp12 in combination with neurotrophic factors |
| 09/15/1999 | EP0941109A1 Pretreatment with growth factors to protect against cns damage |
| 09/15/1999 | EP0941105A1 Pretraumatic use of hemoglobin |
| 09/15/1999 | EP0941104A1 Peptide synthesis with sulfonyl protecting groups |
| 09/15/1999 | EP0941100A2 Pharmaceutical compositions containing lamivudine and zidovudine |
| 09/15/1999 | EP0941097A1 Use of mixtures of active substances for the production of hypocholesteremic agents |
| 09/15/1999 | EP0941096A2 A method for lowering plasma levels of lipoprotein(a) |
| 09/15/1999 | EP0941093A1 Use of nk-1 receptor antagonists for treating major depressive disorders with anxiety |
| 09/15/1999 | EP0941088A1 Use of conjugated linoleic acid to enhance natural killer lymphocyte function |
| 09/15/1999 | EP0941082A2 New use for 1,3-propanediol derivatives |
| 09/15/1999 | EP0941054A1 Use of sterolsulfates as active substances for producing means to inhibit serin proteases |
| 09/15/1999 | EP0832098A4 Method of producing igf-i and igfbp-3 with correct folding and disulfide bonding |
| 09/15/1999 | EP0804239B1 Anti-stress, anti-impairment and anti-aging drug and process for manufacturing thereof |
| 09/15/1999 | EP0759899B1 Nitro compounds and their compositions having anti-inflammatory, analgesic and anti-thrombotic acitivities |
| 09/15/1999 | EP0749421B1 Sulphonamide derivatives as aspartyl protease inhibitors |
| 09/15/1999 | EP0741697B1 Amino acid derivatives and their use as phospholipase a2 inhibitors |
| 09/15/1999 | EP0733051B1 Bicyclic heterocycles as neurokinin a antagonists |
| 09/15/1999 | EP0656001B1 Novel 2-substituted indane-2-mercaptoacetylamide tricyclic derivatives useful as inhibitors of enkephalinase |
| 09/15/1999 | EP0652767B1 Treatment of human lactation failure |
| 09/15/1999 | EP0637242B1 Agents for treating substance abuse disorders |
| 09/15/1999 | CN1228811A Modulators of BRCAI activity |
| 09/15/1999 | CN1228780A Phosphinic acid amides as matrix metalloprotease inhibitors |
| 09/15/1999 | CN1228779A Spirocyclic metalloprotease inhibitors |
| 09/15/1999 | CN1228778A Pyridazino [4,5-b]-quinoline 5-oxide derivatives, their preparation and their use as glycine antagonists |
| 09/15/1999 | CN1228773A Heterocyclic metalloprotease inhibitors |
| 09/15/1999 | CN1228772A Heterocyclic metalloprotease inhibitors |
| 09/15/1999 | CN1228771A 1,3-diheterocyclic metalloprotease inhibitors |
| 09/15/1999 | CN1228770A Compounds having antihypertensive, cardioprotective, anti-ischemic and antilipolytic properties |
| 09/15/1999 | CN1228767A Bidentate metalloprotease inhibitors |
| 09/15/1999 | CN1228698A Antithrombotic and antiatherogenic pharmaceutical composition including thienopyridine derivative and HMG-CoA-reductase inhibitor |
| 09/15/1999 | CN1228697A Method for in vivo reduction of iron levels and compositions useful therefor |
| 09/15/1999 | CN1228696A Use of PKC inhibitors for manufacture of medicament for treatment of AIDS |
| 09/15/1999 | CN1228695A Substituted 1,2,3,4-tetrahydro-2-dibenzofuranamines and 2-aminocyclohepta [b] benzofurans |
| 09/15/1999 | CN1228414A New benzocyclobutane compounds, process for their preparation and pharmaceutical compositions containing them |
| 09/15/1999 | CN1228322A Shanshen Fengru medicinal preparation and its production method |
| 09/15/1999 | CN1045089C 2-(2-amino-1,6-dihydro-6-oxo-purin-9-yl) methoxy-1, 3-propanediol derivative |
| 09/14/1999 | US5952513 Benzo b! thiophene compounds |
| 09/14/1999 | US5952483 Human IκB-β |
| 09/14/1999 | US5952478 Nucleotides and analogs in which both the 3' oxy linkage and the 5' oxy linkage are replaced by carbon linkages; for antisense agents; viricides against influenza, herpes and human immune deficiency virus; anticarcinogenic agents |
| 09/14/1999 | US5952382 Inhibiting the biological effects of an overregulation of retinoid acid receptors and/or of a hypervitaminosis a; treating skin disorder, eye vision defects, skin aging |
| 09/14/1999 | US5952373 Applying to the skin an effective amount of one or more flavonoids |
| 09/14/1999 | US5952369 Pyrrolidinyl hydroxamic acid compounds and their production process |
| 09/14/1999 | US5952368 5-aroylpyrrol-2-ylmethylarene derivatives |
| 09/14/1999 | US5952362 2-imidazoline, 2-oxazoline, 2-thiazoline, and 4-imidazole derivatives of methylphenyl, methoxyphenyl, and aminophenyl alkylsulfonamides and ureas and their use |
| 09/14/1999 | US5952356 Treating diabetes in a mammal with an active material and a glucosidase inhibitor |
| 09/14/1999 | US5952354 Enzyme inhibitors of chloesterol ester hydrolase and/or acyl coenzyme a:chloesterol acyltransferase; inhibit the esterification of chloesterol and reduce absorption through the intestine; carbamates of 4-8 membered azacycloalkanols |
| 09/14/1999 | US5952350 Naphthyl compounds and compositions, as estrogen receptor binding agents |
| 09/14/1999 | US5952344 Treating and control of diseases which represent therapeutic indications for nmda(n-methyl-d-aspertate) receptor subtype specific blokers by administering tetrahydroisoquinoline derivatives |
| 09/14/1999 | US5952343 HIV protease inhibitors |
| 09/14/1999 | US5952342 1,6-naphthyridines effective in treating atherosclerosis, restenosis and psoriasis; anticarcinogenic and -proliferative agents; bactericides |
| 09/14/1999 | US5952333 Inhibitor of tyrosine kinase receptor for treating proliferative disease such as cancer |